SK Biopharm and Latin American pharmaceutical giant establish joint venture to use AI to predict epilepsy - South Korean media

SK Biopharm, a drug development company, has formed a joint venture with Europharma, a major Brazilian pharmaceutical company, to commercialize an AI-based epilepsy management platform.
Prior to this, SK Biopharm and Europharma announced that they would begin selling the new epilepsy drug cenobamate in Latin America from 2022.
With the establishment of the joint venture, the collaboration has expanded to digital healthcare. Since 2018, SK Biopharm has been working with its own brainwave analysis AI technology.
Based on the technology of wearable devices, the company has the technology to predict and monitor patients' seizures in real time. Mentiscare uses SK Biopharm's technology to
The company plans to develop a patient-specific alarm system and a clinical decision support platform that utilizes data, centered on its predictive technology.
Mentiscare plans to create an environment where it can provide support and individualized management. To enter the North American market, Mentiscare has established a base in Toronto, Canada, where the largest healthcare and life insurance company in North America is located.
There are scientific research institutes, startups and investor networks.